Evidence map›Paper›PMID 38938662›Full record

ArticleFrontiers in toxicology2024

Optimisation of an

Fiona Chapman, Luuk de Haan, Linda Gijzen, Wouter Strijker, Edgar Trelles Sticken, Sarah Jean Pour, Roman Wieczorek, Florian Haberstroh, Sandra Otte, Thomas Nahde and 2 more

Abstract read
In one paragraph

Article in Frontiers in toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fiona Chapman *Imperial Brands PLC, Bristol, United Kingdom.
Luuk de Haan *Mimetas BV, Oegstgeest, Netherlands.
Linda GijzenMimetas BV, Oegstgeest, Netherlands.
Wouter StrijkerMimetas BV, Oegstgeest, Netherlands.
Edgar Trelles StickenReemtsma Cigarettenfabriken GmbH, An Imperial Brands PLC Company, Hamburg, Germany.
Sarah Jean PourReemtsma Cigarettenfabriken GmbH, An Imperial Brands PLC Company, Hamburg, Germany.
Roman WieczorekReemtsma Cigarettenfabriken GmbH, An Imperial Brands PLC Company, Hamburg, Germany.
Florian HaberstrohReemtsma Cigarettenfabriken GmbH, An Imperial Brands PLC Company, Hamburg, Germany.
Sandra OtteReemtsma Cigarettenfabriken GmbH, An Imperial Brands PLC Company, Hamburg, Germany.
Thomas NahdeReemtsma Cigarettenfabriken GmbH, An Imperial Brands PLC Company, Hamburg, Germany.
Liam SimmsImperial Brands PLC, Bristol, United Kingdom.
Matthew StevensonImperial Brands PLC, Bristol, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Smoking cigarettes is a cause of serious diseases in smokers, including cardiovascular disease. Through a pathway of endothelial dysfunction, lipid infiltration, macrophage recruitment and vascular remodeling, atherosclerosis is fundamental in the development of most cardiovascular diseases. There is an increasing number of next-generation products (NGP) which provide potentially reduced harm forms of nicotine delivery to adult smokers. This study aimed to optimise an Methods: An aqueous aerosol extract from the 1R6F reference cigarette was compared with two categories of NGP, (a heated tobacco product (HTP) and an electronic nicotine delivery system (ENDS)), to assess relative effects on select atherogenic endpoints (oxidative stress, monocyte adhesion, ICAM-1 expression, and inflammatory markers). Following exposure of THP-1 monocytes with the aqueous extracts, the resulting conditioned medium was then added to the HCAEC vessels. Results: 1R6F was consistently the most potent test article, eliciting observed responses at 4x lower concentrations than applied for both the HTP and ENDS. The HTP was more potent than the ENDS product across all endpoints, however, all test articles increased monocyte adhesion. ICAM-1 did not appear to be a main driver for monocyte adhesion, however, this could be due to replicate variability. Upon comparison to an extract-only control exposure, THP-1-medium pre-conditioning was an important mediator of the responses observed. Conclusion: In conclusion, the data suggests that the NGP extracts, containing primary aerosol chemical constituents exhibit a marked reduction in biological activity in the early key events associated with atherogenesis when compared to a cigarette, adding to the weight of evidence for the tobacco harm reduction potential of such products.

Indexed as

cardiovascular diseasecigaretteco-cultureelectronic nicotine delivery systemheated tobacco

Identifiers

PMID38938662
PMCPMC11208624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.